TYK Medicines, Inc. (H-share; HKEX: 02410) filed its Monthly Return for Equity Issuer covering the period ended 30 April 2026, confirming no changes to share capital and continued compliance with Hong Kong’s public-float requirements.

The company’s registered share capital remained unchanged at 380.07 million H shares, each with a par value of RMB 1, keeping total registered share capital at RMB 380.07 million.

Issued share capital was equally stable: 380.07 million shares were in issue, with zero treasury shares, mirroring the prior month’s figures. Management affirmed that the public float comfortably exceeded the 25% minimum threshold stipulated by Main Board Rule 13.32B.

No new share options, warrants, convertibles, or other equity instruments were issued, and there were no repurchases, cancellations, or Hong Kong Depositary Receipt activities during the month.

The filing was signed by Executive Director, Chairman and Chief Executive Officer Mr. Wu Yusheng on 6 May 2026.